Application of GHRH-A in preparation of medicine for treating non-alcoholic fatty liver diseases

A technology for GHRH-A, fatty liver disease, applied in the field of biomedicine

Pending Publication Date: 2020-03-06
SHENYANG MEDICAL COLLEGE
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Currently, non-specific symptomatic treatments such as lipid-lowering and liver-protecting drugs are mainl

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of GHRH-A in preparation of medicine for treating non-alcoholic fatty liver diseases
  • Application of GHRH-A in preparation of medicine for treating non-alcoholic fatty liver diseases
  • Application of GHRH-A in preparation of medicine for treating non-alcoholic fatty liver diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] The following combination Figure 1~5 , the specific content of the present invention will be described in detail through specific embodiments.

[0022] The invention relates to the application of growth hormone releasing hormone receptor agonist MR-409 in the preparation of non-alcoholic fatty liver disease medicine.

[0023] 1. Materials:

[0024] BKS-Leprem2Cd479 / Nju and C57BL / 6 mice, male, 12 weeks old, animal certificate number: SCXK (Su) 2018-0008, were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. MR-409 was provided by the team of Andrew V. Schally (University of Miami, USA), and was formulated with 10% polyethylene glycol to the required concentration for use.

[0025] 2. Method:

[0026] 2.1 Experimental grouping and administration

[0027] 1) The experimental animals were BKS-Leprem2Cd479 / Nju and C57BL / 6 mice, 12 weeks old, and divided into wild type group (WildType, WT), model group (BKS-Leprem2Cd479 / Nju, DB / DB), and drug treatment group (...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of biomedicine, and mainly relates to an application of a growth hormone releasing hormone receptor stimulant MR-409 in preparation of a drug for treating non-alcoholic fatty liver disease (NAFLD). At present, no targeted drug is provided for treatment of NAFLD, and lipid-lowering drugs and liver-protecting drugs are commonly adopted. MR-409 is novel GHRHR-A, GHRHR is widely expressed in the liver and pancreas, and literature reports that GHRHR-A has the effects of improving the pancreatic function, promoting the survival of transplanted pancreatic islets andrelieving diabetic eye complications. According to the invention, research finds that MR409 can improve non-alcoholic fatty liver disease imageology, serum enzymology, serum metabolism and histologyindexes of diabetic mice, and is expected to become a therapeutic drug for non-alcoholic fatty liver diseases. The invention provides a new application of MR-409 in treating the non-alcoholic fatty liver disease, provides a new strategy for treating the non-alcoholic fatty liver disease, has important clinical treatment significance, and provides a scientific basis for developing the MR-409 into amedicine for treating the non-alcoholic fatty liver disease in the future.

Description

technical field [0001] The invention belongs to the field of biomedicine, and mainly relates to the application of growth hormone releasing hormone receptor agonist MR-409 in the preparation of diabetes nonalcoholic fatty liver disease medicine. Background technique [0002] Nonalcoholic fatty liver disease (NAFLD) refers to the disorder of liver lipid metabolism caused by excluding alcohol and other definite liver damage factors, and is characterized by diffuse hepatic macrovesicular fatty change. syndrome. The patient had no history of excessive alcohol consumption, but his pathological changes were similar to those of alcoholic liver disease (ALD). The disease spectrum included nonalcoholic simple fatty liver, nonalcoholic steatohepatitis, cirrhosis, and liver cancer. Due to increased social pressure, poor eating habits, emotional factors and other reasons, the incidence of NAFLD has increased by 30% year by year. At present, there is no specific drug for the treatment ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/25A61P1/16A61P3/06
CPCA61K38/25A61P1/16A61P3/06
Inventor 周明生蔡瑞平安德魯·维克托·沙利蔡仁治刘月阳唐琪
Owner SHENYANG MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap